OCGN News and Press, Ocugen, Inc. From 04/11/24

NEW YORK, NY / ACCESSWIRE / April 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ:OCGN). Investors who purchased Ocugen securities are encouraged to obtain additional information and a...

2024-04-10 10:20:34 ET More on Ocugen Ocugen: A Speculative Buy In Biotech Growing Clinical Trials To Billion-Dollar Revenues Ocugen stock gains after FDA nod to initiate Phase 3 trial of gene therapy candidate Ocugen advances Phase 1/2 trial for eye disease candidat...

MALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the Committee for...

2024-04-08 07:10:32 ET Ocugen ( NASDAQ: OCGN ) shares gained 7% premarket on Monday after the U.S. Food and Drug Administration (FDA) cleared the firm’s investigational new drug amendment to initiate a late-stage clinical trial of its gene therapy product candidate......

MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the U.S. Food and...

2024-04-07 04:06:09 ET Ocugen (NASDAQ: OCGN) stock price has been one of the best-performing companies in Wall Street this year. It has jumped by more than 218% in 2024, beating some of the best-known brands like Nvidia and Amazon. This surge has boosted its total market cap to over $46...

2024-04-06 06:13:00 ET 3 Top Strategies to Trade Options With Penny Stocks in 2024 Trading penny stocks through options presents a dynamic avenue for investors looking to enhance their portfolios with high-potential, yet affordable securities. The intersection of options trading and p...

2024-04-05 10:56:25 ET More on Ocugen Ocugen: A Speculative Buy In Biotech Growing Clinical Trials To Billion-Dollar Revenues Ocugen slips as accounting errors force restatements Ocugen shares make gains after US court dismisses class action lawsuits Seeking ...

Established Low Dose as Safe and Tolerable Dose in Current OCU410 Clinical Trial DSMB Approval to Proceed with Medium Dose Cohort Dosing Malvern, Pa., April 05, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on dis...

2024-04-02 19:00:11 ET Image source: The Motley Fool. Ocugen (NASDAQ: OCGN) Q4 2023 Earnings Call Apr 02, 2024 , 8:30 a.m. ET Operator Continue reading For further details see: Ocugen (OCGN) Q4 2023 Earnings Call Transcript